Collegium Pharma (COLL) Tops Q4 EPS by 62c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Collegium Reports Fourth-Quarter and Full-Year 2018 Financial Results
February 27, 2019 4:01 PM ESTXtampza® ER Prescriptions Grew 233% in 2018Net Revenue Increased to $73.4 Million for Fourth Quarter 2018 and $280.4 Million for the Full YearCash and Cash Equivalents were $146.6 million as of December 31, 2018, exceeding year-end cash guidance of $145.0 millionConference call scheduled for today at 4:30 p.m. ET
STOUGHTON, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Â Collegium Pharmaceutical, Inc. (Nasdaq:... More
